サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1571545

北米の外用皮膚治療の市場規模、シェア、動向分析レポート：治療分野別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

North America Topical Skin Treatment Market Size, Share & Trends Analysis Report By Therapeutic Area (Skin Cancer, Eczema, Psoriasis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 121 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
北米の外用皮膚治療の市場規模、シェア、動向分析レポート：治療分野別、流通チャネル別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年09月12日
発行: Grand View Research
ページ情報: 英文 121 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の外用皮膚治療市場の成長と動向：

Grand View Research, Incの最新レポートによると、北米の外用皮膚治療市場規模は2024年から2030年にかけて9.60％のCAGRで成長し、2030年には124億5,000万米ドルに達すると予測されています。

北米の皮膚外用治療市場は、いくつかの重要な要因に後押しされ、着実な成長を遂げています。にきび、湿疹、乾癬、皮膚炎などの皮膚疾患の増加により、効果的な治療に対するニーズが高まっています。消費者のスキンケアに対する意識は高まっており、市販の（OTC）ソリューションを好む傾向が明確になっているため、需要はさらに高まっています。さらに、人口の高齢化に伴い、シワやシミといった皮膚の老化の懸念に対処する製品への関心が高まっています。

バイオテクノロジー、特にナノテクノロジーやドラッグデリバリーシステムなどの分野における進歩は、より効果的で的を絞った治療への道を開いています。ゲノミクスや人工知能の飛躍的進歩に後押しされた個別化スキンケアの動向も、成長の有望な道です。

北米における非メラノーマ皮膚がん（NMSC）をターゲットとする外用治療市場は、特に局所パッチのような革新的ドラッグデリバリーシステムにおいて、著しい進歩が見られると予想されます。これらの進歩は、薬剤の浸透性の低さ、局所的な副作用、患者の服薬アドヒアランスの課題など、従来の局所療法の限界に対処することを目的としています。

スキンケアに対する消費者の意識が高まり、高度なニキビ治療が利用できるようになったことは、需要を促進すると予想される主な要因のひとつです。アマゾンやウォルマートなどのeコマース・プラットフォームの台頭により、こうした治療がより身近なものとなり、小売店やオンライン薬局の成長に寄与しています。さらに、これらのプラットフォームが提供する利便性と多様性は、より多くの消費者がにきび治療を探して購入することを奨励しています。

ニキビ治療の選択肢における継続的な技術革新は、重要な成長促進要因です。サン・ファーマやガルデルマのような企業は、それぞれWinleviやTWYNEO Creamのような新製品を発表し、ニキビ治療に斬新で効果的なソリューションを提供しています。これらの製品は副作用が少なく、より良い結果をもたらし、消費者の進化するニーズに応え、成長を促進しています。

戦略的な合併・買収は、製品の上市とともに業界の拡大に重要な役割を果たしています。例えば、2022年1月、Journey Medical Corporationは、FDA承認の局所ミノサイクリン製品を買収し、製品ポートフォリオと地理的リーチを拡大しました。また、2021年8月にはSun PharmaとCassiopeaが米国とカナダにおけるWinleviの販売で提携し、企業が商業的プレゼンスを高めるために戦略的な動きを見せています。

北米の外用皮膚治療市場レポート・ハイライト

  • 治療分野別では、湿疹分野が2023年の市場を独占し、予測期間中に大きく成長すると予測されます。この成長は、湿疹の有病率の上昇、認知度の向上、小児および老年人口の増加によるものです。
  • 流通チャネルに基づくと、2023年には小売薬局セグメントが市場を独占しました。この優位性は、アクセスが広く消費者の信頼を得ていること、処方箋なしで製品を入手できる利便性、薬剤師による個別指導によるものです。
  • 米国が北米の皮膚外用剤市場を独占したのは、その強固なヘルスケア・インフラ、高い医療費、確立された製薬産業によるものです。さらに、先進的な治療オプションが利用可能であることと、製薬会社の強力な販売促進努力が相まって、消費者の高い認知度とアクセスが確保されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 北米の外用皮膚治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
    • 市場機会分析
  • 北米外用皮膚治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析

第4章 北米の外用皮膚治療市場：治療分野の推定・動向分析

  • 北米外用皮膚治療市場：治療分野ダッシュボード
  • 北米の外用皮膚治療市場：治療分野の変動分析
  • 北米の外用皮膚治療市場：治療分野別、収益
  • 皮膚がん
  • 湿疹
  • 乾癬
  • その他の治療分野

第5章 北米の外用皮膚治療市場：流通チャネルの推定・動向分析

  • 北米の外用皮膚治療市場：流通チャネルダッシュボード
  • 北米の外用皮膚治療市場：流通チャネル変動分析
  • 北米の外用皮膚治療市場：流通チャネル別、収益
  • 病院薬局
  • 小売薬局
  • その他

第6章 北米の外用皮膚治療市場：治療領域および流通チャネル別の地域別推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • Key company market share analysis, 2023
    • Johnson &Johnson Services, Inc.
    • GSK Plc
    • Pfizer, Inc.
    • Novartis AG
    • LEO Pharma A/S
    • AbbVie, Inc.
    • Bausch Health Companies, Inc.
    • Galderma
    • Sun Pharmaceutical Industries Ltd.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America topical skin treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America topical skin treatment market, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 4 North America topical skin treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. North America topical skin treatment market, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 6 U.S. topical skin treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 Canada topical skin treatment market, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 8 Canada topical skin treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Mexico topical skin treatment market, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 10 Mexico topical skin treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 North America Topical Skin Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic areas and distribution channel snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Pharmaceutical market value, 2023 (USD billion)
  • Fig. 12 Market trends & outlook
  • Fig. 13 Melanoma cases in 2021
  • Fig. 14 Porter's five force analysis
  • Fig. 15 PESTEL analysis
  • Fig. 16 North America topical skin treatment market: Therapeutic areas outlook and key takeaways
  • Fig. 17 North America topical skin treatment market: Therapeutic areas movement analysis
  • Fig. 18 Skin cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Skin cancer cases in 2022
  • Fig. 20 Fluorouracil (5-FU) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Imiquimod market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Ingenol mebutate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Diclofenac sodium gel market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Tirbanibulin ointment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Eczema market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Prevalence of Atopic Dermatitis (AD) in 2023
  • Fig. 28 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Calcineurin inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Crisaborole (Eucrisa) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Topical antimicrobials market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Emollients and moisturizers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Psoriasis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Psoriasis cases (Million)
  • Fig. 36 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Vitamin D analogs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Coal tar market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Tazarotene market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Topical calcineurin inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Combination therapies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 North America topical skin treatment market: Distribution channel outlook and key takeaways
  • Fig. 45 North America topical skin treatment market: Distribution channel movement analysis
  • Fig. 46 Skin cancer, hospital pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Skin cancer, retail pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Skin cancer, other, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Eczema, hospital pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Eczema, retail pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Eczema, other, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Psoriasis, hospital pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Psoriasis, retail pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Psoriasis, other, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Other, hospital pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Other, retail pharmacy, market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 North America topical skin treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 U.S. North America Topical Skin Treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Canada topical skin treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Mexico topical skin treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Market participant categorization
  • Fig. 66 Company market share analysis, 2023
  • Fig. 67 Strategic framework
目次
Product Code: GVR-4-68040-450-2

North America Topical Skin Treatment Market Growth & Trends:

The North America topical skin treatment market size is anticipated to reach USD 12.45 billion by 2030, growing at a CAGR of 9.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The topical skin treatment market in North America is seeing steady growth, fueled by several key factors. Rising rates of skin conditions like acne, eczema, psoriasis, and dermatitis have created a growing need for effective treatments. Consumers are becoming more aware of skincare and showing a clear preference for over-the-counter (OTC) solutions, further boosting demand. Additionally, as the population ages, there is increasing interest in products that address skin aging concerns, such as wrinkles and age spots.

Advancements in biotechnology, especially in areas like nanotechnology and drug delivery systems, are paving the way for more effective and targeted treatments. The trend toward personalized skincare, driven by breakthroughs in genomics and artificial intelligence, is also a promising avenue for growth.

The market for topical treatments targeting Nonmelanoma Skin Cancer (NMSC) in North America is expected to witness significant advancements, particularly in innovative drug delivery systems like topical patches. These advancements aim to address the limitations of conventional topical therapies, such as poor drug penetration, local adverse effects, and patient adherence challenges.

Increasing consumer awareness about skincare and the availability of advanced acne treatments is one of the major factors expected to drive demand. The rise of e-commerce platforms, such as Amazon and Walmart, has made these treatments more accessible, contributing to the growth of retail and online pharmacies. Moreover, the convenience and variety offered by these platforms have encouraged more consumers to seek out and purchase acne treatments.

Continuous innovations in acne treatment options are crucial growth drivers. Companies like Sun Pharma and Galderma have introduced new products, such as Winlevi and TWYNEO Cream, respectively, which offer novel & effective solutions for acne treatment. These products provide better outcomes with fewer adverse effects, meeting the evolving needs of consumers and driving growth.

Strategic mergers & acquisitions, along with product launches, play a significant role in industry expansion. For instance, in January 2022, Journey Medical Corporation acquired FDA-approved topical minocycline products, expanding its product portfolio and geographical reach. In addition, in August 2021, Sun Pharma and Cassiopea partnered for the distribution of Winlevi in the U.S. and Canada, highlighting the strategic moves companies are making to enhance their commercial presence.

North America Topical Skin Treatment Market Report Highlights:

  • Based on therapeutic area, the Eczema segment dominated the market in 2023 and is anticipated to grow significantly over the forecast period. This growth is attributed due to the rising prevalence of eczema, increasing awareness, and growing pediatric and geriatric populations.
  • Based on distribution channel, the retail pharmacies segment dominated the market in 2023. This dominance is attributed due to their widespread accessibility and consumer trust, convenience of obtaining products without a prescription, and personalized guidance from pharmacists.
  • U.S. dominated the North America market for topical skin treatment owing to its robust healthcare infrastructure, high healthcare expenditure, and a well-established pharmaceutical industry. Furthermore, the availability of advanced treatment options, coupled with strong promotional efforts from pharmaceutical companies, ensures high consumer awareness and access.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic Areas
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic Areas outlook
    • 2.2.2. Distribution Channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Skin Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of skin diseases
      • 3.2.1.2. Increasing adoption of topical treatments
      • 3.2.1.3. Growing demand for faster and more effective results
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Skin irritation and allergies caused by topical drugs
      • 3.2.2.2. Preference for alternative modes of drug delivery
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Emerging biologic topical treatments for psoriasis
      • 3.2.3.2. Innovative topical therapies for nonmelanoma skin cancer
      • 3.2.3.3. Growth potential in advanced acne treatment solutions
  • 3.3. North America Topical Skin Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. North America Topical Skin Treatment Market: Therapeutic Areas Estimates & Trend Analysis

  • 4.1. North America Topical Skin Treatment Market: Therapeutic Areas Dashboard
  • 4.2. North America Topical Skin Treatment Market: Therapeutic Areas Movement Analysis
  • 4.3. North America Topical Skin Treatment Market: By Therapeutic Areas, Revenue (USD million)
  • 4.4. Skin Cancer
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Fluorouracil (5-FU)
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Imiquimod
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Ingenol Mebutate
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Diclofenac Sodium Gel
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Tirbanibulin Ointment
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Eczema
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Corticosteroids
      • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Calcineurin Inhibitors
      • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Crisaborole (Eucrisa)
      • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.5. Topical Antimicrobials
      • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.6. Emollients and Moisturizers
      • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Psoriasis
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.2. Corticosteroids
      • 4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.3. Vitamin D Analogues
      • 4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.4. Coal Tar
      • 4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.5. Tazarotene
      • 4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.6. Topical Calcineurin Inhibitors
      • 4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.7. Combination Therapies
      • 4.6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.8. Others
      • 4.6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other therapeutic areas
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America topical skin treatment market: Distribution Channel Estimates & Trend Analysis

  • 5.1. North America topical skin treatment market: Distribution Channel Dashboard
  • 5.2. North America topical skin treatment market: Distribution Channel Movement Analysis
  • 5.3. North America topical skin treatment market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America topical skin treatment market: Regional Estimates & Trend Analysis By Therapeutic Areas, and Distribution Channel

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company market share analysis, 2023
    • 7.3.2. Johnson & Johnson Services, Inc.
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. GSK Plc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Pfizer, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Novartis AG
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. LEO Pharma A/S
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. AbbVie, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Bausch Health Companies, Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Galderma
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Sun Pharmaceutical Industries Ltd.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives